Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

European Journal of Cancer

Volumn 73, Issue , 2017, Pages 1-8

  Cuzzubbo, S ^a,b   Javeri, F ^a   Tissier, M ^a   Roumi, A ^a   Barlog, C ^a,b   Doridam, J ^a,b   Lebbe, C ^c   Belin, C ^a,b   Ursu, R ^a,b   Carpentier, A F ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Anti CTLA4; Anti PD1; Immune checkpoint inhibitors; Neurological adverse events

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; TICILIMUMAB; UNCLASSIFIED DRUG; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

BRAIN DISEASE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INCIDENCE; MENINGITIS; MYELITIS; NEUROLOGIC DISEASE; NEUROMUSCULAR JUNCTION DISORDER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; INCIDENCE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85008315530     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.12.001     Document Type: Review

References (95)

1. [1] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
2. [2] Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., Dummer, R., Wolchok, J.D., Schmidt, H., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16:5 (2015), 522–530.
3. [3] Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
4. [4] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
5. [5] Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
6. [6] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
7. [7] Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:21 (2015), 2018–2028.
8. [8] Rizvi, N.A., Mazieres, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:3 (2015), 257–265.
9. [9] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015), 1803–1813.
10. [10] Kourie, H.R., Klastersky, J., Immune checkpoint inhibitors side effects and management. Immunotherapy 8:7 (2016), 799–807.
11. [11] Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
12. [12] Tabchi, S., Messier, C., Blais, N., Immune-mediated respiratory adverse events of checkpoint inhibitors. Curr Opin Oncol 28:4 (2016), 269–277.
13. [13] Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med, 9, 2011, 204.
14. [14] Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:2 (2010), 155–164.
15. [15] Yang, J.C., Hughes, M., Kammula, U., Royal, R., Sherry, R.M., Topalian, S.L., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:8 (2007), 825–830.
16. [16] Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:19 (2010), 3167–3175.
17. [17] McDermott, D.F., Drake, C.G., Sznol, M., Choueiri, T.K., Powderly, J.D., Smith, D.C., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33:18 (2015), 2013–2020.
18. [18] Motzer, R.J., Rini, B.I., McDermott, D.F., Redman, B.G., Kuzel, T.M., Harrison, M.R., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33:13 (2015), 1430–1437.
19. [19] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
20. [20] Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Perez-Gracia, J.L., Han, J.Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016), 1540–1550.
21. [21] Patnaik, A., Kang, S.P., Rasco, D., Papadopoulos, K.P., Elassaiss-Schaap, J., Beeram, M., et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:19 (2015), 4286–4293.
22. [22] Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:8 (2015), 908–918.
23. [23] Robert, C., Ribas, A., Wolchok, J.D., Hodi, F.S., Hamid, O., Kefford, R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:9948 (2014), 1109–1117.
24. [24] Liao, B., Shroff, S., Kamiya-Matsuoka, C., Tummala, S., Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16:4 (2014), 589–593.
25. [25] Shirai, T., Sano, T., Kamijo, F., Saito, N., Miyake, T., Kodaira, M., et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46:1 (2016), 86–88.
26. [26] Gettings, E.J., Hackett, C.T., Scott, T.F., Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler, 21(5), 2015, 670.
27. [27] Khoja, L., Maurice, C., Chappell, M., MacMillan, L., Al-Habeeb, A.S., Al-Faraidy, N., et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4:3 (2016), 175–178.
28. [28] LaPorte, J., Solh, M., Ouanounou, S., Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma. J Oncol Pharm Pract 23:1 (2017 Jan), 71–74.
29. [29] Bhatia, S., Huber, B.R., Upton, M.P., Thompson, J.A., Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 32:2 (2009), 203–205.
30. [30] Maurice, C., Schneider, R., Kiehl, T.R., Bavi, P., Roehrl, M.H., Mason, W.P., et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res 3:12 (2015), 1299–1302.
31. [31] Gaudy-Marqueste, C., Monestier, S., Franques, J., Cantais, E., Richard, M.A., Grob, J.J., A severe case of ipilimumab-induced Guillain-Barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36:1 (2013), 77–78.
32. [32] Mandel, J.J., Olar, A., Aldape, K.D., Tremont-Lukats, I.W., Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 344:1–2 (2014), 229–231.
33. [33] Manousakis, G., Koch, J., Sommerville, R.B., El-Dokla, A., Harms, M.B., Al-Lozi, M.T., et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 48:3 (2013), 440–444.
34. [34] Stein, M.K., Summers, B.B., Wong, C.A., Box, H.L., Cleveland, K.O., Meningoencephalitis following ipilimumab administration in metastatic melanoma. Am J Med Sci 350:6 (2015), 512–513.
35. [35] Ansell, S.M., Hurvitz, S.A., Koenig, P.A., LaPlant, B.R., Kabat, B.F., Fernando, D., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 15:20 (2009), 6446–6453.
36. [36] Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113:7 (2009), 1581–1588.
37. [37] Hersh, E.M., O'Day, S.J., Powderly, J., Khan, K.D., Pavlick, A.C., Cranmer, L.D., et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investig New Drugs 29:3 (2011), 489–498.
38. [38] Hodi, F.S., Lee, S., McDermott, D.F., Rao, U.N., Butterfield, L.H., Tarhini, A.A., et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:17 (2014), 1744–1753.
39. [39] Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
40. [40] Le, D.T., Lutz, E., Uram, J.N., Sugar, E.A., Onners, B., Solt, S., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:7 (2013), 382–389.
41. [41] Maki, R.G., Jungbluth, A.A., Gnjatic, S., Schwartz, G.K., D'Adamo, D.R., Keohan, M.L., et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma, 2013, 2013, 168145.
42. [42] McDermott, D., Haanen, J., Chen, T.T., Lorigan, P., O'Day, S., Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 24:10 (2013), 2694–2698.
43. [43] O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21:8 (2010), 1712–1717.
44. [44] Robert, C., Schadendorf, D., Messina, M., Hodi, F.S., O'Day, S., Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 19:8 (2013), 2232–2239.
45. [45] Royal, R.E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U.S., et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:8 (2010), 828–833.
46. [46] Slovin, S.F., Higano, C.S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J.J., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24:7 (2013), 1813–1821.
47. [47] Small, E.J., Tchekmedyian, N.S., Rini, B.I., Fong, L., Lowy, I., Allison, J.P., A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:6 (2007), 1810–1815.
48. [48] Weber, J., Hamid, O., Amin, A., O'Day, S., Masson, E., Goldberg, S.M., et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun, 13, 2013, 7.
49. [49] Weber, J.S., O'Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:36 (2008), 5950–5956.
50. [50] Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol 76:5 (2015), 997–1004.
51. [51] Zimmer, L., Eigentler, T.K., Kiecker, F., Simon, J., Utikal, J., Mohr, P., et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med, 13, 2015, 351.
52. [52] Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PloS One, 10(3), 2015, e0118564.
53. [53] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
54. [54] Calabro, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14:11 (2013), 1104–1111.
55. [55] Calabro, L., Morra, A., Fonsatti, E., Cutaia, O., Fazio, C., Annesi, D., et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 3:4 (2015), 301–309.
56. [56] Camacho, L.H., Antonia, S., Sosman, J., Kirkwood, J.M., Gajewski, T.F., Redman, B., et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:7 (2009), 1075–1081.
57. [57] Chung, K.Y., Gore, I., Fong, L., Venook, A., Beck, S.B., Dorazio, P., et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 28:21 (2010), 3485–3490.
58. [58] Comin-Anduix, B., Lee, Y., Jalil, J., Algazi, A., de la Rocha, P., Camacho, L.H., et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med, 6, 2008, 22.
59. [59] Huang, R.R., Jalil, J., Economou, J.S., Chmielowski, B., Koya, R.C., Mok, S., et al. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 17:12 (2011), 4101–4109.
60. [60] Joshua, A.M., Monzon, J.G., Mihalcioiu, C., Hogg, D., Smylie, M., Cheng, T., A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res 25:4 (2015), 342–347.
61. [61] Kirkwood, J.M., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 16:3 (2010), 1042–1048.
62. [62] Ralph, C., Elkord, E., Burt, D.J., O'Dwyer, J.F., Austin, E.B., Stern, P.L., et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 16:5 (2010), 1662–1672.
63. [63] Ribas, A., Chesney, J.A., Gordon, M.S., Abernethy, A.P., Logan, T.F., Lawson, D.H., et al. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med, 10, 2012, 236.
64. [64] Ribas, A., Kefford, R., Marshall, M.A., Punt, C.J., Haanen, J.B., Marmol, M., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31:5 (2013), 616–622.
65. [65] Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 20:9 (2014), 2424–2432.
66. [66] Straatsma, B.R., Nusinowitz, S., Young, T.A., Gordon, L.K., Chun, M.W., Rosen, C., et al. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol 143:6 (2007), 958–969.
67. [67] von Euw, E., Chodon, T., Attar, N., Jalil, J., Koya, R.C., Comin-Anduix, B., et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med, 7, 2009, 35.
68. [68] Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:4 (2015), 311–319.
69. [69] Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
70. [70] Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:18 (2015), 2004–2012.
71. [71] Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:34 (2015), 4015–4022.
72. [72] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
73. [73] Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:10 (2014), 1020–1030.
74. [74] Ulmeanu, R., Antohe, I., Anisie, E., Antoniu, S., Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study. Expert Rev Anticancer Ther 16:2 (2016), 165–167.
75. [75] Weber, J.S., Kudchadkar, R.R., Yu, B., Gallenstein, D., Horak, C.E., Inzunza, H.D., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:34 (2013), 4311–4318.
76. [76] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:26 (2015), 2509–2520.
77. [77] Armand, P., Nagler, A., Weller, E.A., Devine, S.M., Avigan, D.E., Chen, Y.B., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31:33 (2013), 4199–4206.
78. [78] Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:21 (2015), 2006–2017.
79. [79] Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:2 (2013), 122–133.
80. [80] Conry, R.M., Sullivan, J.C., Nabors, L.B. 3rd, Ipilimumab-induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 3:6 (2015), 598–601.
81. [81] O'Kane, G.M., Lyons, T.G., Colleran, G.C., Ahmad, M.W., Alken, S., Kavanagh, E.C., et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 37:12 (2014), 757–760.
82. [82] Ali, S., Lee, S.K., Ipilimumab therapy for melanoma a mimic of leptomeningeal metastases. Am J Neuroradiol 36:12 (2015), E69–E70.
83. [83] Bompaire, F., Mateus, C., Taillia, H., De Greslan, T., Lahutte, M., Sallansonnet-Froment, M., et al. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs 30:6 (2012), 2407–2410.
84. [84] Luke, J.J., Lezcano, C., Hodi, F.S., Murphy, G.F., Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. J Clin Oncol 33:6 (2015), e32–e35.
85. [85] Thaipisuttikul, I., Chapman, P., Avila, E.K., Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 38:2 (2015), 77–79.
86. [86] Altman, A.L., Golub, J.S., Pensak, M.L., Samy, R.N., Bilateral facial palsy following ipilimumab infusion for melanoma. Otolaryngol Head Neck Surg 153:5 (2015), 894–895.
87. [87] Bot, I., Blank, C.U., Boogerd, W., Brandsma, D., Neurological immune-related adverse events of ipilimumab. Pract Neurol 13:4 (2013), 278–280.
88. [88] Wilgenhof, S., Neyns, B., Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 22:4 (2011), 991–993.
89. [89] Jinnur, P., Lim, K.G., Severe acute orthopnea: ipilimumab-induced bilateral phrenic nerve neuropathy. Lung 193:4 (2015), 611–613.
90. [90] Johnson, D.B., Saranga-Perry, V., Lavin, P.J., Burnette, W.B., Clark, S.W., Uskavitch, D.R., et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 33:33 (2015), e122–e124.
91. [91] Loochtan, A.I., Nickolich, M.S., Hobson-Webb, L.D., Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52:2 (2015), 307–308.
92. [92] Hoftberger, R., Rosenfeld, M.R., Dalmau, J., Update on neurological paraneoplastic syndromes. Curr Opin Oncol 27:6 (2015), 489–495.
93. [93] Williams, T.J., Benavides, D.R., Patrice, K.A., Dalmau, J.O., de Avila, A.L., Le, D.T., et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:8 (2016), 928–933.
94. [94] Weber, J.S., Dummer, R., de Pril, V., Lebbe, C., Hodi, F.S., Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119:9 (2013), 1675–1682.
95. [95] Hottinger, A.F., Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29:6 (2016 Dec), 806–812.